Weekly dose of erlotinib shows decreased duodenal polyp burden and side effects for patients with FAP - Mayo Clinic

Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis

Clinical Trial Results National Cancer Institute

Clinical Trial Results National Cancer Institute

Cancer News - Medical Professionals - Mayo Clinic

WO2020236562A1 - Methods for treating familial adenomatous polyposis - Google Patents

Hereditary Polyposis Syndromes Current Treatment Options in Gastroenterology

NCCN Colon Cancer

PDF) Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial

Drug Combination Reduces Number of Colorectal Polyps in Patients with Hereditary Cancer Syndrome - Cancer Health